Sangui Biotech International Inc - Current report filing (8-K)
06 Octubre 2008 - 4:25PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
FORM
8-K
CURRENT
REPORT PURSUANT
TO
SECTION 13 OR 15 (d) OF THE
SECURITIES
EXCHANGE
ACT OF 1934
Date of
Report (Date of earliest event reported):
February 14, 2007
SANGUI
BIOTECH INTERNATIONAL, INC.
(Exact
Name of Registrant as Specified in Its Charter)
Colorado
(State or
Other Jurisdiction of Incorporation)
000-21271
84-1330732
(Commission
File
Number) (IRS
Employer Identification No.)
Alfred-Herrhausen-Str.
44, 58455 Witten, Germany
(Address
of Principal Executive Offices) (Zip Code)
011-49-2302-915-204
(Registrant's
Telephone Number, Including Area Code)
N/A
(Former
Name or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
Item
5.02
Departure
of Directors or Principal Officers; Election of Directors; Appointment of
Principal Officers
Resignation
of Director
On
September 30, 2008, Prof. Dr. Dr. Wolfgang Barnikol submitted his resignation as
a Director of the Board of Directors of the Registrant, effective as of
September 30, 2008. There were no disagreements between the Registrant and
Dr. Barnikol that led to his resignation.
Item
8.01 Other Events
Legal
Proceedings
The
Registrant has been made aware of the fact that its former President, CEO, CFO
and Director, Prof. Dr. Dr. Wolfgang Barnikol has been found jointly and
severally liable to Dr. Rainer Felfe, a shareholder of the Registrant, in a
civil suit for the amount of approximately 700,000 euros (approximately US
$952,000), which amount includes interest and costs, in a judgment rendered
September 13, 2007 by the District Appeal Court of Dusseldorf, Germany
(Oberlandesgericht Düsseldorf I 6 U 96/06). This judgment is enforceable, but
has not yet become final and absolute as Dr. Barnikol has submitted a petition
of appeal to the Federal Supreme Court of Germany (Bundesgerichtshof). The
Registrant was not and is not a party to these proceedings.
Addtionally,
the Registrant has been made aware of a judgment rendered by the District Court
of Dusseldorf (Landgericht Düsseldorf 7 O 299/04), dated September 2, 2008,
finding former President, CEO, CFO and Director, Prof. Dr. Dr. Wolfgang Barnikol
jointly and severally liable to another shareholder of the Registrant in a civil
suit for the amount of approximately 150,000 euros (approximately US $204,000),
which amount includes interest and costs. This judgment is preliminarily
enforceable, but has not yet become final and absolute. The Registrant was not
and is not a party to these proceedings.
On
February 14, 2007,
Dr. Rainer Felfe, filed a claim
(4 Ca
431/07)
against the Registrant and its subsidiary, SanguiBioTech
GmbH, with the
Industrial
Relations Court in Bochum, Germany (Arbeitsgericht
Bochum
). Dr. Felfe's claim states that he
is
entitled
to receive outstanding wages and salaries owed to Prof. Dr. Dr. Wolfgang
Barnikol by the Registrant, or its subsidiary, in the amount of
approximately 370,000 euros (approximately US $503,200) as partial
relief of a judgment rendered in the civil case in the District
Appeal Court of Dusseldorf, Germany (Oberlandesgericht Düsseldorf I 6
U 96/06). Dr. Barnikol has never made a claim against the Registrant,
or its subsidiary, for outstanding wages with any governmental
agency and acknowledges there are no outstanding wages are due to him by
either the Registrant or its subsidiary.
The
claim by Dr. Felfe has been declared pending by the Industrial Relations Court
until a final judgment is rendered by the Federal Supreme Court.
The
Registrant believes the claim lacks merit and plans
to
vigorously defend this claim.
The
Registrant intends to file amended reports for the quarters ended March 31,
2007, September 30, 2007, December 31, 2007, and March 31, 2008 as well as for
the fiscal year ended June 30, 2007 to fully reflect the above
information.
Change
in Date of Annual Meeting
The
Registrant
is
currently preparing its financial statements for its fiscal year ended June 30,
2008. The ensuing report on Form 10-KSB will be filed with the Securities
and Exchange Commission and made public in due course. It will be included
in the proxy materials for the forthcoming annual shareholders' meeting; this
was also requested in a letter by the Securities and Exchange Commission with
regard to the Registrant's 14A filing. Subsequently, the shareholders'
meeting will be delayed by a few weeks. Shareholders will be informed
about the meeting schedule immediately after the board of directors confirm a
new meeting date and file an amended 14A. The Registrant has
issued a press release announcing the delay in the annual
shareholders' meeting date, and a copy of the press release is
included as exhibit 99.1 to this report on Form 8-K.
Item
9.01. Financial Statements and Exhibits.
|
Exhibit No.
|
|
Description
|
|
|
|
|
99.1
|
|
Press
Release
|
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the Registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.
Sangui Biotech
International, Inc.
Date: October
3, 2008
/s/ Thomas Striepe
_______________________________________
By:
Thomas Striepe
Its: President
Sangui Biotech (CE) (USOTC:SGBI)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Sangui Biotech (CE) (USOTC:SGBI)
Gráfica de Acción Histórica
De May 2023 a May 2024
